Search This Blog

Friday, April 30, 2021

Mesoblast Med Cuts Mortality in Patients Under 65 Years With Moderate/Severe COVID-19 ARDS

 

  • Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old

  • In these patients the benefit was further increased when remestemcel-L was used with dexamethasone as part of standard of care

  • Mortality reduction by remestemcel-L was accompanied by increased days alive off mechanical ventilation and reduced days in hospital

  • Plan to meet with U.S. Food and Drug Administration (FDA) to discuss potential next steps

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.